Delivery Order SPE2DB25D3008-SPE2DB26FRBEV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) at a ceiling value of $3,835.96. This contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) with a ceiling value of $1,463.20. This is a firm fixed price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) under a firm fixed-price contract with a ceiling value of $1,238.72. The contract, which is not set-aside and competitively awarded, is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) with a ceiling value of $1,197.73. This is a firm fixed price delivery order with no set-aside designation, meaning the contract was competitively awarded. The performance location is AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania, with an ultimate completion date of June 3, 2025. This delivery order represents a child...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,989.67 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on October 20, 2025, with completion targeted for October 21, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) valued at $2,843.25 on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, firm fixed price delivery order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $4,205.06 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract is classified as a child award under AmerisourceBergen's larger Indefinite...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB26FRBEVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) under a firm fixed-price contract with a ceiling value of $1,075.24. This non-set-aside competitive award is a child contract derived from AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling through December 2026. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of October 23, 2025. This delivery order supports the federal government's pharmaceutical supply chain for military and veteran healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of federal contract awards with DLA for medical products spanning multiple therapeutic domains, from diabetes and neurological medications to vaccines and specialized medical supplies. The firm fixed-price structure and small contract value reflect routine pharmaceutical procurement operations typical of the DLA's medical supply chain operations, which serve defense and federal health system requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/22/25 |